Early-onset Alzheimer’s Disease

Early-onset Alzheimer’s Disease (EOAD) refers to Alzheimer's symptoms appearing before age 65, often with genetic components. Unlike late-onset AD, EOAD typically has a more aggressive progression. In AI governance, EOAD detection tools are classified as high-risk AI systems under the EU AI Act (Article 9) and must comply with ISO 42001 standards. Companies must ensure data-centric approaches that account for genetic diversity,-and implement robust bias detection to prevent discriminatory outcomes. This requires a combination of clinical validation and AI-specific risk management frameworks to meet both healthcare regulations and AI ethics standards.

Enterprise application of EOAD detection AI involves three critical steps: Data-centric Risk Management (ensuring compliance with GDPR Article 9 and Taiwan's PIPA), Model-centric Risk Management (validating AI performance against ISO 42001 and NIST AI RTO standards), and Process-centric Risk Management (establishing post-market monitoring). For example, a company deploying the Eye-AD framework must be closely monitoring AUC-score-based KPIs (target >0.90). If the AUC drops by more than 5% in real-world deployment, the company must trigger a formal retraining and re-validation protocol to mitigate clinical and legal risks. This structured approach ensures the AI remains a reliable tool for early intervention, which is critical for both patient outcomes and company liability management.

Taiwan enterprises face three primary challenges: Regulatory Complexity (navigating the Medical Device Act and AI-specific regulations), Data Scarcity (EOAD cases are rare, making it difficult to train unbiased models), and Ethical Accountability (who is liable for AI-driven misdiagnosis?). To overcome these, companies should: 1) Partner with academic medical centers for high-quality, ethically sourced datasets; 2) Adopt AI Explainability (XAI) techniques to meet the transparency requirements of the EU AI Act; and 3) Invest in AI-specialized legal and technical consultants. A phased approach starting with a 90-day compliance foundation, followed by iterative model refinement, is recommended for sustainable growth.

Winners Consulting Services Co., Ltd. specializes in Early-onset Alzheimer’s Disease for Taiwan enterprises, delivering compliant management systems within 90 days. Free consultation: https://winners.com.tw/contact